N-(4-bromobutyl)cyclohexane-1,2-dicarboximide | 99012-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-(4-bromobutyl)cyclohexane-1,2-dicarboximide
• 英文别名: 2-(4-Bromobutyl)-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione
• CAS: 99012-87-0
• 化学式: C₁₂H₁₈BrNO₂
• 分子量: 288.184
• InChiKey: SRPOBUPCZPCBAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2925190090

反应信息

• 作为反应物：
  描述：

  N-(4-bromobutyl)cyclohexane-1,2-dicarboximide 在 盐酸 、 potassium iodide 、 potassium carbonate 作用下， 以 N-甲基乙酰胺 、 水 为溶剂， 以72.8%的产率得到N-[4-{4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidinyl}butyl]cyclohexane-1,2-dicarboximide
  参考文献：
  名称：

  Imide derivatives and their pharmaceutical use

  摘要：

  该式的化合物：##STR1## 或其酸加盐，可用作抗精神病药物。

  公开号：

  US04937249A1
• 作为产物：
  描述：

  六氢邻苯二甲酰亚胺 生成 N-(4-bromobutyl)cyclohexane-1,2-dicarboximide
  参考文献：
  名称：

  Imide derivatives and compositions for use as antipsychotic agents

  摘要：

  公式为：##STR1## 其中 A 是一个羰基团或磺酰基；B 是以下任何一个式子之一：##STR2##（其中 E 是一个亚甲基、乙烯基或氧原子，一条实线和一条虚线 () 表示单键或双键），##STR3##（其中 F 是一个亚甲基或乙烯基，一条实线和一条虚线 () 的定义如上）和##STR4##（其中 R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5和R.sup.6是氢原子或甲基），当 A 代表羰基团时，B 是1,2-苯基基团，当 A 代表磺酰基时；D 是一个乙烯基、乙烯基或乙炔基，其中一个或多个可以选择性地取代羟基；n 是0、1或2的整数，或其酸盐。这些化合物对于治疗精神病有用。

  公开号：

  US04745117A1

文献信息

• N-(substituted piperazinyl) alkylbicyclic succinimide derivatives
  申请人：Sumitomo Chemical Company, Limited

  公开号：US04598078A1

  公开（公告）日：1986-07-01

  A succinimide derivative of the formula: ##STR1## wherein A is straight or branched C.sub.2 -C.sub.6 alkylene or alkenylene, B is straight or branched C.sub.3 -C.sub.5 alkylene, D is straight or branched C.sub.2 -C.sub.3 alkylene, E is straight or branched C.sub.2 -C.sub.3 alkylene, R.sup.1 and R.sup.2 are each hydrogen or C.sub.1 -C.sub.4 alkyl, or they may form a single bond and R.sup.3 is a phenyl group optionally substituted with C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen and/or trifluoromethyl, a 2-pyridyl group optionally substituted with halogen, a 2-pyrimidyl group optionally substituted with halogen, a group of the formula: ##STR2## (in which R.sup.4 is hydrogen or phenyl), a group of the formula: CO--R.sup.5 (in which R.sup.5 is adamantyl or furyl) or hydroxy (C.sub.2 -C.sub.4) alkyl, and an acid addition salt thereof, which are useful as anti-anxiety drugs and/or anti-allergic drugs.

  一种琥珀酰亚胺衍生物的化学式：##STR1## 其中A是直链或支链的C.sub.2 -C.sub.6烷基或烯基，B是直链或支链的C.sub.3 -C.sub.5烷基，D是直链或支链的C.sub.2 -C.sub.3烷基，E是直链或支链的C.sub.2 -C.sub.3烷基，R.sup.1和R.sup.2分别是氢或C.sub.1 -C.sub.4烷基，或它们可以形成单键，R.sup.3是苯基，可选择地取代为C.sub.1 -C.sub.4烷基，C.sub.1 -C.sub.4烷氧基，卤素和/或三氟甲基，一个可选择地取代为卤素的2-吡啶基，一个可选择地取代为卤素的2-嘧啶基，一个化学式的基团：##STR2##（其中R.sup.4是氢或苯基），一个化学式的基团：CO--R.sup.5（其中R.sup.5是金刚烷基或呋喃基）或羟基（C.sub.2 -C.sub.4）烷基，以及其酸盐加合物，可用作抗焦虑药物和/或抗过敏药物。
• Imide derivatives and compositions for use as antipsychotic agents
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US04745117A1

  公开（公告）日：1988-05-17

  A compound of the formula: ##STR1## wherein A is a carbonyl group or a sulfonyl group; B is either one of the formulas: ##STR2## (in which E is a methylene group, an ethylene group or an oxygen atom and a full line accompanying a broken line ( ) indicates a single bond or a double bond), ##STR3## (in which F is a methylene group or an ethylene group and a full line accompanying a broken line ( ) is as defined above) and ##STR4## (in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each a hydrogen atom or a methyl group) when A represents a carbonyl group, or B is a 1,2-phenylene group when A represents a sulfonyl group; D is an ethylene group, an ethenylene group or an ethynylene group, of which one or more may be optionally substituted with hydroxyl; and n is an integer of 0, 1 or 2, or its acid addition salt. These compounds are useful for the treatment or psychosis.

  公式为：##STR1## 其中 A 是一个羰基团或磺酰基；B 是以下任何一个式子之一：##STR2##（其中 E 是一个亚甲基、乙烯基或氧原子，一条实线和一条虚线 () 表示单键或双键），##STR3##（其中 F 是一个亚甲基或乙烯基，一条实线和一条虚线 () 的定义如上）和##STR4##（其中 R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5和R.sup.6是氢原子或甲基），当 A 代表羰基团时，B 是1,2-苯基基团，当 A 代表磺酰基时；D 是一个乙烯基、乙烯基或乙炔基，其中一个或多个可以选择性地取代羟基；n 是0、1或2的整数，或其酸盐。这些化合物对于治疗精神病有用。
• Succinimide derivatives and their production
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：EP0109562A1

  公开（公告）日：1984-05-30

  A succinimide derivative of the formula: wherein A is straight or branched C2-C6 alkylene or alkenylene, B is straight or branched C3-C5 alkylene, D is straight or branched C2-C3 alkylene, E is straight or branched C2-C3 alkylene, R1 and R2 are each hydrogen or C1-C4 alkyl, or they may form a single bond and R3 is a phenyl group optionally substituted with C1-C4 alkyl, C1-C4 alkoxy, halogen and or trifluoromethyl, a 2-pyridyl group optionally substituted with halogen, a 2-pyrimidyl group optionally substituted with halogen, a group of the formula: (in which R4 is hydrogen or phenyl), a group of the formula: CO-R5 (in which R5 is adamantyl or furyl) or hydroxy(C2-C4)alkyl, and an acid addition salt thereof, which are useful as anti-anxiety drugs and/or anti-allergic drugs.

  一种琥珀酰亚胺衍生物，其式如下 其中 A 为直链或支链 C2-C6 亚烷基或烯基，B 为直链或支链 C3-C5 亚烷基，D 为直链或支链 C2-C3 亚烷基，E 为直链或支链 C2-C3 亚烷基，R1 和 R2 各为氢或 C1-C4 烷基，或它们可形成单键，R3 为任选被 C1-C4 烷基、C1-C4 烷氧基、卤素和或三氟甲基取代的苯基，任选被卤素取代的 2-吡啶基，任选被卤素取代的 2-嘧啶基，式中的一个基团： (其中 R4 为氢或苯基）、式中的一个基团： CO-R5（其中 R5 为金刚烷基或呋喃基）或羟基（C2-C4）烷基，以及它们的酸加成盐，可用作抗焦虑药和/或抗过敏药。
• Imide derivatives, their production and use
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0314098A2

  公开（公告）日：1989-05-03

  A compound of the formula: or its acid addition salt, which is useful as a psychotic drug.

  一种式子为 或其酸加成盐，可用作精神病药物。
• Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies
  作者：Magid Abou-Gharbia、Usha R. Patel、Michael B. Webb、John A. Moyer、Terrance H. Andree、Eric A. Muth

  DOI：10.1021/jm00402a023

  日期：1988.7

  A series of polycyclic aryl- and heteroarylpiperazinyl imides were prepared and tested in various receptor-binding and behavioral tests. Parameters measured included in vitro inhibition of D2 and 5-HT1A receptor binding, inhibition of apomorphine (APO) induced stereotyped and climbing behavior, and activity in blocking conditioned avoidance responding (CAR). Several compounds demonstrated moderate to high affinity for the 5-HT1A receptor binding site; compounds 27 and 36 containing the serotonin mimetic (o-methoxyphenyl)piperazinyl moiety and compounds 42 and 50 containing the 2-pyrimidinylpiperazinyl moiety displayed the highest affinity, being equal to that of the 5-HT1A agonist 8-OH-DPAT (Ki = 1-1.3 nM). In addition to affinity at 5-HT1A binding sites, many compounds were active in blocking CAR. Compound 34, 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]hexahydro-4,7-etheno-1H- cyclobut[f]isoindole-1,3(2H)-dione, demonstrated 3 times the activity of buspirone, blocking CAR in rats with an AB50 of 13 mg/kg. It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors. Compound 34 was selected for further preclinical and pharmacokinetic evaluations for possible development as an anxiolytic agent. Structure-activity relationships within this series are discussed.